Singapore Hsa Medical Device Registration Consultant
Before paying for tests or filing with Singapore's Health Sciences Authority (HSA), establish whether the product is a medical device, its Singapore risk class, the qualifying registration route, and who will hold the registration. A consultant's useful output is a documented route decision and evidence-gap plan—not a promise of approval or a generic submission checklist.
First decision: device status, intended use and risk class
Start from the Singapore-labelled intended medical purpose, claims, operating principle, user and patient population. Separate a general medical device from an in-vitro diagnostic (IVD); apply HSA's relevant risk-classification guidance (GN-13 or GN-14), including software-specific guidance when appropriate. An overseas class, CE mark or FDA clearance does not itself establish the Singapore class. Class A is exempt from product registration, but HSA requires a Class A product notification through SHARE for devices manufactured or imported, and relevant dealer licensing still needs assessment. For Classes B–D, registration is ordinarily needed before supply unless a specific authorised exception applies.
Route-choice matrix: decide before compiling the dossier
The following is an initial decision map, not an eligibility determination. Check HSA's current registration guide and GN-15 for the device-specific conditions and excluded categories.
| Risk class / case | Candidate route | Decision gate before commitment |
|---|---|---|
| Class A | Product-registration exemption; Class A notification | Confirm the classification, manufacture/import activity and dealer-licence position; do not mistake exemption for unrestricted sale. |
| Class B | Full; abridged; immediate where qualified | Check eligible reference approval(s), matching labelled use, worldwide safety/rejection history and—where relevant—documented marketing duration. |
| Class C | Full; abridged; expedited; limited immediate route | Test ECR conditions/exclusions. Immediate Class C is restricted to qualifying standalone medical mobile applications, not all Class C products. |
| Class D | Full; abridged; expedited where qualified | Check two independent qualifying reference approvals for expedited evaluation and HSA's excluded device categories; no general Class D immediate route. |
Without qualifying prior reference approval, the full evaluation route is the default for Classes B–D. Abridged generally requires at least one qualifying reference approval for the same labelled use. Expedited and immediate routes impose further conditions; reference-market approval alone is not enough. HSA's Priority Review Scheme is separate and concerns eligible full-route applications, not an automatic waiver.
Evidence-reuse and gap-analysis matrix
Compare the exact Singapore configuration and intended use with each foreign approval and the existing technical dossier. Classify each item as usable, adaptable or missing before commissioning new studies.
| Existing asset | Mismatch to investigate | Strategic action |
|---|---|---|
| Approval certificates and marketing history | Different indication, model/version, reference approval type, dates, rejection or field-action record | Build approval-to-Singapore-use crosswalk; verify the actual eligibility, not just certificate possession. |
| Technical file and clinical/performance evidence | Outdated reports, weak linkage to claims, software version or IVD intended population | Map to the applicable HSA CSDT/IMDRF submission guide; scope only defensible additional evidence. |
| Labels, IFU and configuration list | Singapore claims, accessories, grouping or model names diverge from approvals | Freeze the intended-use statement and configuration boundary; reassess grouping before dossier assembly. |
| QMS, manufacturer sites and safety surveillance | Certificates not covering relevant sites/activities, unresolved complaints or FSCA | Confirm dossier and dealer QMS evidence separately; close material safety gaps or select a different route. |
Five gates before any filing or new testing
Use a staged decision record. An unresolved gate should become an explicit hold point, not be hidden in the application.
- Freeze intended use, promotional claims, medical-device status, IVD/non-IVD type and provisional Singapore risk class.
- Inventory model families, accessories, software versions and candidate grouping; compare intended configurations with existing approvals.
- Verify each reference approval's current status, independent agency, matching labelled use, safe-marketing history and any rejection, withdrawal or safety action.
- Score CSDT/IMDRF sections as ready, adaptable or missing; assign owners and determine whether extra testing or clinical/performance work is actually necessary.
- Confirm Singapore registrant, relevant manufacturer/importer/wholesaler licensing and post-market responsibilities; approve the route and only then launch submission work.
Who decides and who executes
The product owner controls the technical truth and releases evidence; a Singapore registrant manages product-registration accountability and HSA communications; a manufacturer, importer or wholesaler assesses its own dealer-licence obligations. These roles may overlap but are not interchangeable. A consultant should provide a written classification rationale, route comparison, assumptions and disqualifiers, gap register, sequencing recommendation and unresolved questions for HSA—without representing itself as HSA or promising a result.
Once the strategy is approved, use the relevant neighbouring page for execution rather than treating this advisory page as a filing manual:
Three red flags that change the recommendation
An IVD with a changed clinical intended use cannot automatically reuse a non-identical foreign approval. A Class C implant may be excluded from expedited evaluation even with overseas approvals. A device presented as Class A may still require notification and dealer-licence analysis. For each, pause the shortest-route assumption, document the decisive missing fact and check the HSA source before committing expenditure.
Official HSA starting points
Questions to resolve before hiring a registration consultant
Does a CE mark or FDA clearance guarantee abridged registration?
No. Verify the specific qualifying approval, the same Singapore-labelled intended use, reference-agency criteria, safety history and exclusions; an overseas classification alone is insufficient.
Is a Class A device outside HSA oversight?
No. Class A is exempt from product registration, but product notification for manufactured/imported devices and applicable dealer-licence and post-market duties must still be assessed.
Can every Class C device use immediate registration?
No. HSA limits that Class C route to qualifying standalone medical mobile applications and imposes additional conditions. Other Class C devices need another eligible route.
Can an existing EU technical file be reused unchanged?
Do not assume so. Compare claims, configurations, clinical/performance data, labels, safety history and current HSA dossier format; reuse is decided item by item.
Should we appoint a registrant before choosing the route?
Identify a suitable Singapore registrant early, but settle intended use, class, route and evidence gaps together. Clarify who holds registration and how changes, post-market events and a future registrant switch will be managed.